



ANSWERS



Acquisition of HalioDx

Positioning for Global Cancer Diagnostics Growth

June 1, 2021

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the anticipated acquisition of HalioDx; statements regarding the expected timing for completion of the transaction; statements related to the expected benefits of the proposed transaction, including but not limited to future revenues, revenue growth and gross margin accretion, HalioDx's Immunoscore technology's value in both clinical care, including in colorectal cancer diagnostics, and biopharma collaborations, and HalioDx's manufacturing capabilities and potential synergies with the nCounter system. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to, the possibility that the transaction may not be pursued following French works council review; that the closing conditions to the proposed transaction may not be satisfied or waived, including a governmental entity may not grant a required regulatory approval; delay in closing the transaction or the possibility of non-consummation of the transaction; the risk of stockholder litigation in connection with contemplated transaction; the retention of HalioDx employees and Veracyte's ability to successfully integrate the HalioDx business; and risks inherent in the achievement of anticipated synergies and the timing thereof. Additional factors that may impact these forward-looking statements can be found in Item 1A—"Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and in our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, "Know by Design" and "More about You" are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license. Immunoscore is the registered trademark of Inserm in the U.S. and selected countries and used by HalioDx under license.




Our vision is to improve
outcomes for patients all
over the world at every
step of their journey.



Accelerating revenue growth in 2021 and beyond

Solidifies clear strategy to achieve our global vision



Expands Veracyte's global leadership team



Vincent Fert
Chairman &
CEO



Stéphane Debono
Deputy CEO



Corinne Danan
EVP Pharma BU &
Corporate Affairs




Dr. Jérôme Galon
Chief Scientific Officer



Fabienne Hermitte, Ph.D.
VP Global Medical,
Regulatory & Quality

IVD manufacturer leading in the emerging field of immuno-oncology

- Commercial-stage company with over 200 employees and 2 CLIA labs in France and U.S.
- Providing diagnostic tests and biopharma services for measuring immune response to cancer
- >15-year track record across global quality, regulatory and operations for genomic based contract diagnostic test development and manufacturing
- Two key commercial business areas
 - **Immunoscore®**: Enables extraction of spatially organized tissue molecular information for oncologists and biopharma to assess patient immune response to cancer
 - **IVD**: World-class development and manufacturing operation
- Proven proprietary technology, based on over 15 years of research, 6,000 patients and 8 publications
 - Immunoscore Colon has been included in the 2020 ESMO Clinical Practice Guidelines



HalioDx – Global Growth

Provides European manufacturing and operations


End-to-end ability to control our distributed test business



A	B	C	D	E	Total
1,383 m ²	429 m ²	502 m ²	147 m ²	180 m ²	2,935 m ²

- Supports global expansion of distributed-testing and enables us to prioritize adding new tests to the nCounter system
 - Envisia (adapted to nCounter by end of 2021)
 - Percepta Nasal Swab (development in 2022 with anticipated commercial launch in 2023)
 - Decipher: opportunities to add prostate and bladder cancer tests
 - Additional menu development
- Provides physical footprint to manufacture test kits for the nCounter platform
- Quality and regulatory infrastructure to support global business
- Transitioning manufacturing of our test kits to HalioDx is expected to be accretive to our gross margins, particularly as we continue to grow the nCounter installed base and test menu


Extends our scientific capabilities to immuno-oncology



- Complementary immuno-oncology biomarker analysis technology supports our vision of answering important clinical questions along the patient-care continuum
 - Potential to help further inform patient care – from treatment decisions to risk for recurrence – and help improve outcomes
- Halio’s Immunogram multimodal analysis platform can help biopharma partners understand and predict patient response to immunotherapy; anticipated to fuel biopharma services business
- Proven technology with significant clinical evidence



Immunoscore measures impact of immune cells on cancer progression



**The more T lymphocytes
have infiltrated the tumor,
the better the patient's
chances of survival^{1, 2}**


from a tumor-centric to an
immune contexture view
of cancer evolution

1 Pages et al. Effector memory T cells, early metastasis, and survival in colorectal cancer., N Engl J Med. 2005 Dec 22;353(25):2654-66.

2 Galon J. et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome Science 313, 1960 (2006);

HalioDx – Menu Expansion


Expands Veracyte's market into colorectal cancer



With HalioDx, we would address 8 of top 10 cancers*

* U.S. incidence
Source: Evaluate Pharma Forecasts
Note: Incidence based on US population in 2022.
© Veracyte, Inc. All rights reserved.

Near-term commercial opportunity in colorectal cancer



Acquisition consideration for HalioDx


Total Consideration: €260 million

~60% Cash

+

~40% Equity

Accelerating growth while significantly expanding our operational capability




HalioDx 2021 revenue contribution to Veracyte dependent on:

- Transaction close date
- Exchange rate
- Purchase accounting

2021 guidance will be updated after transaction closes

Solidifies global leadership in cancer diagnostics



~\$50 BILLION LONG-TERM GLOBAL TAM



Strategic Rationale

- Unlocking value through addition of global manufacturing infrastructure and operations, scientific excellence and broadened testing menu to address 8 of 10 top cancers¹

Key Terms

- €260 million in total consideration to HalioDx security holders (~€147 million in cash and up to ~€113 million in stock)
- Number of Veracyte shares issued will be based on 10-day volume-weighted trading average prior to the closing date

Locations

- HalioDx's operations and laboratories will remain in Marseille, France and Richmond, Virginia

Conditions and Timing

- Upon completion of the required works council consultations, Veracyte expects that the shareholders of HalioDx will enter into the definitive purchase agreement with Veracyte for the purchase and sale of HalioDx
- Unanimously approved by Veracyte's board and fully supported by the HalioDx's board of directors
- Expected to close in the third fiscal quarter of 2021

